POSTERS & PUBLICATIONS
From the latest randomized trials and methodologies to solid research results, find all the information you need. Click on any media below to download.
POSTERS
Society for Immunotherapy of Cancer (SITC) Annual Meeting (2024)
11.2024
Society for Immunotherapy of Cancer (SITC) Annual Meeting (2024)
Phase 2 study of pembrolizumab (Pemb) plus plinabulin (Plin) and docetaxel (Doc) for patients with metastatic NSCLC after failure on first-line immune checkpoint inhibitor alone or combination therapy: updated efficacy and safety results on immune re-sensitization
European Society for Medical Oncology (ESMO) Congress 2024
09.2024
European Society for Medical Oncology (ESMO) Congress 2024
Plinabulin/Docetaxel vs. Docetaxel in Survival Benefits of 2L/3L EGFR Wild-Type NSCLC after Platinum Regimens (DUBLIN-3): a Randomized Phase 3 Trial
International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (2024)
09.2024
Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): a Phase 3 Randomized Controlled Trial
Society for Immunotherapy of Cancer (SITC) Annual Meeting (2023)
11.2023
Society for Immunotherapy of Cancer (SITC) Annual Meeting (2023)
Immune Activation with Plinabulin Enhances Anti-tumor Response Combining Radiation with Immune Checkpoint Blockade
Society for Immunotherapy of Cancer (SITC) Annual Meeting (2024)
11.2024
Society for Immunotherapy of Cancer (SITC) Annual Meeting (2024)
Phase 2 study of pembrolizumab (Pemb) plus plinabulin (Plin) and docetaxel (Doc) for patients with metastatic NSCLC after failure on first-line immune checkpoint inhibitor alone or combination therapy: updated efficacy and safety results on immune re-sensitization
European Society for Medical Oncology (ESMO) Congress 2024
09.2024
European Society for Medical Oncology (ESMO) Congress 2024
Plinabulin/Docetaxel vs. Docetaxel in Survival Benefits of 2L/3L EGFR Wild-Type NSCLC after Platinum Regimens (DUBLIN-3): a Randomized Phase 3 Trial
PUBLICATIONS
Lancet 2024
09.2024
The Lancet Respiratory Medicine
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
JNCCN 2023
09.2023
JNCCN
Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy
JAMA Network Open 2022
01.27.2022
JAMA
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced
Neutropenia in Patients With Solid Tumors
JAMA Oncology 2020
09.24.2020
JAMA Oncology
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced
Neutropenia in Patients With Solid Tumors
Lancet 2024
09.2024
The Lancet Respiratory Medicine
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
JNCCN 2023
09.2023
JNCCN
Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy